Anthem Biosciences Limited (NSE:ANTHEM)

Anthem Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	5,918	4,513	3,673	3,852	4,055
Depreciation & Amortization	1,341	893.71	818.24	637.74	578.35
Other Amortization	-	0.78	0.78	0.78	-
Loss (Gain) From Sale of Assets	0.28	4.37	4.29	-0.53	1.65
Loss (Gain) From Sale of Investments	-48.86	-73.78	-	-	-
Stock-Based Compensation	158.59	343.46	-	-	-
Provision & Write-off of Bad Debts	5.73	20.44	-	-	-
Other Operating Activities	-323.7	10.86	-474.93	-393.69	82.75
Change in Accounts Receivable	-1,261	330.23	-2,164	521.31	-715.29
Change in Inventory	2,159	-1,291	-819.31	-711.86	-231.67
Change in Accounts Payable	-348.7	93.75	288	71	-120.84
Change in Other Net Operating Assets	844.91	-2,140	75.13	-916.75	-321.21
Operating Cash Flow	8,445	2,706	1,402	3,060	3,329
Operating Cash Flow Growth	212.14%	93.04%	-54.20%	-8.09%	19.91%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-2,112	-2,612	-2,900	-1,889	-1,558
Sale of Property, Plant & Equipment	37.72	22.75	6.91	0.7	0.55
Sale (Purchase) of Intangibles	-	-	-8.55	-56.17	-31.39
Investment in Securities	-5,695	459.32	274.07	-2,262	-637.06
Other Investing Activities	752.82	664.36	413.38	446.62	171.48
Investing Cash Flow	-7,016	-1,466	-2,215	-3,760	-2,055

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	-	-	919.91	-	-
Long-Term Debt Issued	-	-	154.7	902.9	-
Total Debt Issued	-	-	1,075	902.9	-
Short-Term Debt Repaid	-385.93	-589.41	-	-7.16	-506.97
Long-Term Debt Repaid	-208	-664.96	-	-	-138.23
Total Debt Repaid	-593.93	-1,254	-	-7.16	-645.2
Net Debt Issued (Repaid)	-593.93	-1,254	1,075	895.74	-645.2
Issuance of Common Stock	265.65	-	-	-	2,475
Repurchase of Common Stock	-	-	-1,831	-	-
Preferred Dividends Paid	-	-	-	-	-0.01
Dividends Paid	-	-	-	-	-0.01
Other Financing Activities	-71.7	-102.11	-15.19	-256	-23.03
Financing Cash Flow	-399.98	-1,356	-771.81	639.74	1,807

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	-2.71	-4.13	-	-	-
Miscellaneous Cash Flow Adjustments	0.01	0.01	-	0.01	-
Net Cash Flow	1,026	-120.74	-1,585	-60.56	3,081

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	6,333	93.43	-1,499	1,171	1,771
Free Cash Flow Growth	6678.51%	-	-	-33.91%	9.44%
Free Cash Flow Margin	29.74%	0.51%	-10.55%	11.06%	14.27%
Free Cash Flow Per Share	11.16	0.17	-2.64	2.05	3.10
Levered Free Cash Flow	5,549	1,049	-2,186	305.5	963.49
Unlevered Free Cash Flow	5,589	1,111	-2,129	355.97	1,036

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	63.8	100.93	90.76	66.85	100.86
Cash Income Tax Paid	2,040	1,590	1,200	1,150	1,230
Change in Working Capital	1,394	-3,007	-2,620	-1,036	-1,389

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error